Home > Urology > EAU 2021 > Bladder Cancer > ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer

ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer

Presented By
Prof. Jürgen Gschwend, Technical University Munich, Germany
Conference
10:32:15pm> hello nurse from conference
Trial
Phase 3, IMvigor010, IMvigor011
In the IMvigor010 trial, post-surgical circulating tumour DNA (ctDNA) positivity was associated with a high risk of recurrence and death. ctDNA positivity identified patients with muscle-invasive bladder cancer (MIBC) likely to derive survival benefits from adjuvant atezolizumab. Tumour mutation burden status was also associated with improved outcomes with adjuvant atezolizumab in the ctDNA-positive population [1]. “ctDNA has substantial potential to be used throughout the individual patient journey,” Prof. Jürgen Gschwend (Technical University Munich, Germany) explained. It could be useful in many phases, from screening to monitoring for resistance in post-treatment care. For example, ctDNA could be useful to determine the need for treatment intensification, such as the need for perioperative therapy. Post-surgery presence of ctDNA in patients with bladder cancer indicates molecular disease progression that precedes clinical relapse. Prof. Gschwend argued...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on